Medical News

RSS

Generex reports positive trends in ongoing Oral-lyn buccal insulin spray global Phase III trial

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

29 Jul 2010

Genetic interaction with diet causes variations in metabolic traits

Ever notice some people seem to eat anything they want and never gain a pound, while others seem to gain weight just by looking at fattening foods. You may be seeing things correctly after all. According to research published in the July 2010 issue of Genetics, this may have a biological cause. Using fruit flies, researchers have found that genes interacting with diet, rather than diet alone, are the main cause of variation in metabolic traits, such as body weight. This helps explain why some diets work better for some people than others, and suggests that future diets should be tailored to an individual's genes rather than to physical appearance.

29 Jul 2010

LeMaitre Vascular second-quarter sales increase 12% $14.2mm

LeMaitre Vascular, Inc., a provider of peripheral vascular devices and implants, today announced Q2 2010 financial results. The Company posted record quarterly sales of $14.2mm and record quarterly operating income of $2.0mm. The Company also increased its share repurchase program to $5mm and raised its sales and operating income guidance for 2010.

29 Jul 2010

Nanotechnology approaches to solve major problems on global scale: Report

Nanotechnology refers to a broad range of tools, techniques and applications that simply involve particles on the approximate size scale of a few to hundreds of nanometers in diameter. Particles of this size have some unique physicochemical and surface properties that lend themselves to novel uses. Indeed, advocates of nanotechnology suggest that this area of research could contribute to solutions for some of the major problems we face on the global scale such as ensuring a supply of safe drinking water for a growing population, as well as addressing issues in medicine, energy, and agriculture.

29 Jul 2010

Mapping NTDs is critical for controlling, treating diseases

Mapping neglected tropical diseases (NTDs) is vital for efforts to control and treat diseases, write the authors of an editorial published Tuesday in PLoS Neglected Tropical Diseases, ANI/Sindh Today reports (7/28).

29 Jul 2010

Loss of key nerve cells cause Parkinson's disease: Research

Scientists at the Stanford University School of Medicine have identified a molecular pathway responsible for the death of key nerve cells whose loss causes Parkinson's disease. This discovery not only may explain how a genetic mutation linked to Parkinson's causes the cells' death, but could also open the door to new therapeutic approaches for the malady.

29 Jul 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Odyssey Healthcare second-quarter net patient service revenue increases 3.5% to $176.2 million

Odyssey HealthCare, Inc., one of the largest providers of hospice care in the United States, today announced financial results for the three and six months ended June 30, 2010.

29 Jul 2010

Scientists study mutant protein lump formation process to control brain cell death

Australian scientists have identified the behaviour of the mutant protein 'huntingtin' which leads to the fatal Huntington's disease providing potential targets to treat the disease, a University of Melbourne study reveals.

29 Jul 2010

Insurers post strong earnings, but may hold back on bragging rights

Two leading insurers reported second-quarter earnings with rising profits this week.

29 Jul 2010

FDA approves Cuvposa Oral Solution for chronic severe drooling in children

The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years.

29 Jul 2010

Humana collaborates with HealthCompare to facilitate online health insurance

Humana, one of the nation's leading health and supplemental benefits companies, has entered into an arrangement with HealthCompare,a one-stop online guide to help individuals and families easily research, compare, buy and enroll in a health insurance plan at the right price. While this arrangement is new for Humana and HealthCompare, it builds on both organizations' efforts to help consumers make healthcare decisions with confidence and success.

29 Jul 2010

Metabolix second-quarter net loss decreases to $9.5 million

Metabolix, Inc., a bioscience company focused on developing sustainable solutions for plastics, chemicals and energy, today reported financial results for the three months ended June 30, 2010.

29 Jul 2010

GOP continues call for health law repeal; Census releases uninsured data

The Washington Post: New census data reveal big differences among states in the rate of uninsured people under age 65. Massachusetts has the lowest rate, 7.8 percent, and Texas the highest, 26.8 percent. "The statistics are for 2007 and show health insurance coverage by state and for each of the country's roughly 3,140 counties. The numbers do not include the impact on millions of people who lost their jobs and health insurance after the recession began in December 2007."

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Bioniche, Synerx announce FDA approval and launch of Isosulfan Blue Injection 1%

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC announced today the FDA approval and launch of Isosulfan Blue Injection 1%.

29 Jul 2010

Cerner second-quarter revenue increases 13% to $456.0 million

Cerner Corporation today announced results for the 2010 second quarter that ended July 3, 2010, delivering strong levels of bookings, revenue, earnings and cash flow.

29 Jul 2010

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

Rite Aid agrees to pay $1 million to settle medical privacy questions

The Wall Street Journal: "Rite Aid Corp. agreed to pay $1 million to settle potential violations of government privacy rules after regulators said it failed to protect customers' and employees' financial and medical information. The drug-store chain's agreement with the Federal Trade Commission requires the company to establish an information-security program and obtain a third-party audit of its compliance to that effect every two years for the next 20 years."

29 Jul 2010

Response Biomedical closes $8 million common share private placement

Response Biomedical Corporation announced today that it has closed its previously announced private placement of common shares for gross proceeds of approximately $8 million. The Company issued 13,333,333 common shares at a price of C$0.60 per share.

29 Jul 2010